CD19 and acute lymphoblastic leukemia: Blinatumomab (Blincyto) is used as a therapy for acute lymphoblastic leukemia (ALL) that targets CD19 on B cells and engages T cells through linked anti-CD3 binding (51); tebentafusp-tebn (Kimmtrak, Immunocore Ltd.), a bispecific gp100 peptide–HLA–directed CD3 TCE, was approved for patients with unresectable or metastatic uveal melanoma (30), supporting the importance of this approach.